Sarepta Therapeutics (NASDAQ:SRPT) Downgraded to Market Perform Rating by BMO Capital Markets
BMO Capital Markets downgraded shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) from an outperform rating to a market perform rating in a research note published on Monday morning, Marketbeat reports. They currently have $70.00 price objective on the biotechnology company’s stock, down from their previous price objective of $120.00. SRPT has been the subject […]
BMO Capital Markets downgraded shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) from an outperform rating to a market perform rating in a research note published on Monday morning, Marketbeat reports. They currently have $70.00 price objective on the biotechnology company’s stock, down from their previous price objective of $120.00. SRPT has been the subject […]
